224 related articles for article (PubMed ID: 28741484)
1. Suzanne Cory: Life-and-Death Switches: the Rise of BH3 Mimetics.
Trends Cancer; 2016 Oct; 2(10):537-539. PubMed ID: 28741484
[No Abstract] [Full Text] [Related]
2. ABT-199 for chronic lymphocytic leukemia.
Seymour J
Clin Adv Hematol Oncol; 2014 Oct; 12(10):698-700. PubMed ID: 25658896
[No Abstract] [Full Text] [Related]
3. Venetoclax (Venclexta) for chronic lymphocytic leukemia.
Med Lett Drugs Ther; 2016 Aug; 58(1500):101-2. PubMed ID: 27466751
[No Abstract] [Full Text] [Related]
4. A BH3 Mimetic for Killing Cancer Cells.
Green DR
Cell; 2016 Jun; 165(7):1560. PubMed ID: 27315468
[TBL] [Abstract][Full Text] [Related]
5. Venetoclax, the first BCL-2 inhibitor for use in patients with chronic lymphocytic leukemia.
Seymour J
Clin Adv Hematol Oncol; 2019 Aug; 17(8):440-443. PubMed ID: 31449511
[No Abstract] [Full Text] [Related]
6. Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors.
Thijssen R; Slinger E; Weller K; Geest CR; Beaumont T; van Oers MH; Kater AP; Eldering E
Haematologica; 2015 Aug; 100(8):e302-6. PubMed ID: 25957396
[No Abstract] [Full Text] [Related]
7. Therapeutics targeting Bcl-2 in hematological malignancies.
Ruefli-Brasse A; Reed JC
Biochem J; 2017 Oct; 474(21):3643-3657. PubMed ID: 29061914
[TBL] [Abstract][Full Text] [Related]
8. Pathways and mechanisms of venetoclax resistance.
Bose P; Gandhi V; Konopleva M
Leuk Lymphoma; 2017 Sep; 58(9):1-17. PubMed ID: 28140720
[TBL] [Abstract][Full Text] [Related]
9. Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax.
Blombery P; Thompson ER; Nguyen T; Birkinshaw RW; Gong JN; Chen X; McBean M; Thijssen R; Conway T; Anderson MA; Seymour JF; Westerman DA; Czabotar PE; Huang DCS; Roberts AW
Blood; 2020 Mar; 135(10):773-777. PubMed ID: 31951646
[TBL] [Abstract][Full Text] [Related]
10. Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies.
Roberts AW; Huang D
Clin Pharmacol Ther; 2017 Jan; 101(1):89-98. PubMed ID: 27806433
[TBL] [Abstract][Full Text] [Related]
11. Targeting MCL1, Companies Aim to Unblock Apoptosis.
Cancer Discov; 2019 May; 9(5):572. PubMed ID: 30944116
[TBL] [Abstract][Full Text] [Related]
12. Pioneering apoptosis-targeted cancer drug poised for FDA approval.
Mullard A
Nat Rev Drug Discov; 2016 Mar; 15(3):147-9. PubMed ID: 26931080
[No Abstract] [Full Text] [Related]
13. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S
Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989
[TBL] [Abstract][Full Text] [Related]
14. Targeting BCL-2-like Proteins to Kill Cancer Cells.
Cory S; Roberts AW; Colman PM; Adams JM
Trends Cancer; 2016 Aug; 2(8):443-460. PubMed ID: 28741496
[TBL] [Abstract][Full Text] [Related]
15. Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies.
Yalniz FF; Wierda WG
Drugs; 2019 Aug; 79(12):1287-1304. PubMed ID: 31313099
[TBL] [Abstract][Full Text] [Related]
16. Potential of BCL2 as a target for chronic lymphocytic leukemia treatment.
Moia R; Diop F; Favini C; Kodipad AA; Gaidano G
Expert Rev Hematol; 2018 May; 11(5):391-402. PubMed ID: 29561706
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic development and current uses of BCL-2 inhibition.
Roberts AW
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):1-9. PubMed ID: 33275682
[TBL] [Abstract][Full Text] [Related]
18. Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia.
Roberts AW; Stilgenbauer S; Seymour JF; Huang DCS
Clin Cancer Res; 2017 Aug; 23(16):4527-4533. PubMed ID: 28100580
[TBL] [Abstract][Full Text] [Related]
19. Targeting BCL2 for the treatment of lymphoid malignancies.
Anderson MA; Huang D; Roberts A
Semin Hematol; 2014 Jul; 51(3):219-27. PubMed ID: 25048785
[TBL] [Abstract][Full Text] [Related]
20. New Agents to Treat Chronic Lymphocytic Leukemia.
Zaman F; Savendahl L
N Engl J Med; 2016 Jun; 374(22):2185. PubMed ID: 27248632
[No Abstract] [Full Text] [Related]
[Next] [New Search]
